Clinical trial
Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors
NCT00063973 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2003
- Completion date
- Not reported
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
childhood central nervous system germ cell tumor, childhood choroid plexus tumor, childhood craniopharyngioma, childhood ependymoblastoma, childhood grade i meningioma, childhood grade ii meningioma, childhood grade iii meningioma, childhood high-grade cerebellar astrocytoma, childhood high-grade cerebral astrocytoma, childhood infratentorial ependymoma, childhood low-grade cerebellar astrocytoma, childhood low-grade cerebral astrocytoma, childhood medulloepithelioma, childhood mixed glioma, childhood oligodendroglioma, childhood supratentorial ependymoma, recurrent childhood brain stem glioma, recurrent childhood brain tumor, recurrent childhood cerebellar astrocytoma, recurrent childhood cerebral astrocytoma, recurrent childhood ependymoma, recurrent childhood medulloblastoma, recurrent childhood pineoblastoma, recurrent childhood subependymal giant cell astrocytoma, recurrent childhood supratentorial primitive neuroectodermal tumor, recurrent childhood visual pathway and hypothalamic glioma